Search
Blog Post
Esophageal Cancer Q&A with Dr. Fountzilas
… Esophageal Cancer Q&A with Dr. Fountzilas April is Esophageal Cancer Awareness Month. Here, Christos Fountzilas, MD , Associate Professor of Oncology and …
Education
Trainees' Accomplishments and Highlights
… B, Foster BA, Rajan P, Attwood K, Chatley S, Iyer R, Fountzilas C, Bakin AV. A synergistic two-drug therapy … , Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Selective therapeutic strategy for …
News
Roswell Park Becomes Region’s Only NPF Center for Pancreatic Cancer
… access to state-of-the-art clinical trials,” adds Christos Fountzilas, MD , NPF Program Director at Roswell Park. “I … access to state-of-the-art clinical trials,” adds Christos Fountzilas, MD , NPF Program Director at Roswell Park. “I …
Cancer Types
Symptoms of Esophageal Cancer
… of Esophageal Cancer Esophageal Cancer Q&A with Dr. Fountzilas Like many cancer types, esophageal cancer does not … opinion Risk factors … Esophageal Cancer Q&A with Dr. Fountzilas Like many cancer types, esophageal cancer does not …
Pancreatic Cancer Research Center
… Clinical trials Recent publications 2025 Patel R, Fountzilas C, Horowitz M, Schultz E, Clayback KM, Knudsen ES, … PMC11839031. 2024 Hagerty BL, Fekrmandi F, Schneider T, Fountzilas C, Stiles Z, Kukar M, Calvo B, Cherkassky L. …
Blog Post
Can you have liver cancer and not know it?
… that is significantly damaged,” according to Christos Fountzilas, MD, FACP , Assistant Professor of GI Medical … fluke is a common cause of liver cancer, according to Dr. Fountzilas. More commonly, however, tumors or cancer in the …
Clinical Trial
A PHASE 1, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF TORL-3-600 IN PARTICIPANTS WITH ADVANCED CANCER
… STUDY OF TORL-3-600 IN PARTICIPANTS WITH ADVANCED CANCER I Fountzilas, Christos This first-in-human study will evaluate …
Blog Post
New options for KRAS-associated cancers available at Roswell Park
… — or who develop resistance — to the drug,” says Christos Fountzilas, MD, FACP, Associate Professor of Oncology and … in my trial takes a different approach,” explains Dr. Fountzilas. “It binds to the KRAS molecule and breaks it …